Alvotech has entered key supply and commercialization agreements with Sandoz to expand biosimilar treatments in Canada and across Australia and New Zealand. The deal covers multiple therapeutic areas—ophthalmology, immunology, and gastroenterology—and positions both companies to broaden patient access through shared responsibilities in development, manufacturing, and distribution.
Subscribe
Biotechnology
Industry News
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
Key Takeaways:
• Alvotech-Sandoz Partnership
• Coverage Spans Canada, Australia, and New Zealand
• Biosimilar Focus for Ophthalmology, Immunology, and Gastroenterology
• Alvotech Oversees Development and Manufacturing; Sandoz Leads Commercialization
• Agreements Aim to Strengthen Patient Access to Affordable Treatments
The Biosimilar Deal in Focus
Alvotech, a global biotechnology company specializing in the development and manufacture of biosimilar medicines, signed supply and commercialization agreements with Sandoz, a firm dedicated to improving patient access to biologic treatments. According to Alvotech, these partnerships aim to broaden patient access across critical markets and strengthen its portfolio in anticipation of regulatory approvals.
Regional Coverage and Therapeutic Areas
In Canada, the arrangement centers on a biosimilar candidate in ophthalmology: a prefilled syringe intended for intravitreal injection. Meanwhile, in Australia and New Zealand, Alvotech and Sandoz have committed to advancing three biosimilar candidates designed for immunology and gastroenterology needs. Each of these products is intended to address specific patient demands in the region.
Shared Responsibilities
“These agreements with Sandoz further advance Alvotech’s strategy of securing commercial pathways for its biosimilars portfolio across global markets ahead of regulatory approval,” said Róbert Wessman, Chairman. Under the deal, Alvotech remains in charge of the research, development, and global clinical activities, as well as manufacturing the biosimilar products. Sandoz takes on the role of managing regulatory submissions, commercialization efforts, and distribution across each of the designated territories.
Key Biosimilar Highlights
| Biosimilar Name | Therapy Area | Territories |
|---|---|---|
| Candidate 1 | Ophthalmology | Canada |
| Candidate 2 | Immunology/Gastro | Australia & New Zealand |
| Candidate 3 | Immunology/Gastro | Australia & New Zealand |
| Candidate 4 | Immunology/Gastro | Australia & New Zealand |
(Note: Candidate names and additional details remain undisclosed; this table summarizes the therapy areas and coverage based on the original announcement.)
Patient Access and Global Outlook
Sandoz, known for its commitment to delivering affordable biologic medicines, will helm the distribution of these biosimilars with the support of Alvotech’s development infrastructure. Both companies highlight that this collaboration is intended to bolster patient access by introducing more sustainable, cost-effective treatment options once regulatory approvals are secured.
The agreements underscore the continued momentum in the biosimilars market, suggesting a growing emphasis on collaboration to expand global reach. As these partnerships progress, Alvotech and Sandoz hope their joint effort will serve as a model for future initiatives aimed at delivering vital healthcare products worldwide.
